Clinical Trial Update: Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports termination of a Phase 1/2 study of temsirolimus intended to reverse androgen insensitivity in castration-resistant prostate …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Temsirolimus (temsirolimus)

Snippet

Sponsor: Sandy Srinivas | Conditions: Prostate Cancer, Prostatic Neoplasms | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2014-10-13